Table 1. Factors that increase the risk of severe sinusoidal liver injury resulting from the conditioning regimen. Refer to Appendix 3 for abbreviations.

Liver diseases at baseline	Specific conditioning regimens	Concomitant drugs during conditioning therapy
Inflammatory diseases	Cyclophosphamide-based	Itraconazole
Chronic hepatitis B or C	CY 120 mg/kg + TBI (greater risk with higher TBI dosing)	Sirolimus (rapamycin)
Non-alcoholic steatohepatitis	BCV (BCNU + CY + VP-16)	Norethisterone
Alcoholic hepatitis	BU + CY (greater risk without therapeutic drug monitoring of BU)
Fibrotic diseases	Melphalan-based
Cirrhosis	BU + MEL + thiotepa
Lobular fibrosis	BU + MEL
Extramedullary hematopoiesis with sinusoidal fibrosis	Other regimens
Cholestatic disorders	BU + TBI (greater risk with higher TBI dosing)
Jaundice caused by intrahepatic cholestasis	Gemtuzumab ozogamicin-containing myeloablative regimens
Past history	High-dose radiolabeled antibody myeloablative regimens
Prior SOS from conventional chemotherapy
Recent exposure to gemtuzumab ozogamicin
Prior liver irradiation
Prior myeloablative hematopoietic cell transplant